QuidelOrtho Reports Third Quarter 2026 Financial Results
PR Newswire•03/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $619 million, down 12% year over year
- ➤Adjusted diluted EPS $0.31; GAAP diluted loss per share $0.78
- ➤2027 cost program expected to deliver over $80 million annual savings
- ➤2026 revenue guidance narrowed to $2.52-$2.54 billion
- ➤2026 adjusted EBITDA guidance narrowed to $540-$545 million
Expert Statements
Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho
“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base.”
Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho
“While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program.”
Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho
“This program is designed to improve profitability and cash flow while evolving our operating model around the distinct needs of our customers and markets.”
Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho
“We believe these actions will help mitigate near-term headwinds and position the Company for sustainable long-term growth.”
QuidelOrtho Reports Third Quarter 2026 Financial Results PR Newswire
― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ―
Get started
Create a free account to read the full story.